BOSTON & TEL AVIV, Israel--(BUSINESS WIRE)--FeelBetter, the leading provider of polypharmacy patient management technology and pioneer of Pharmaco-Clinical Intelligence, today announced a collaboration on a prospective research study with investigators at Brigham and Women’s Hospital in Boston. The research will assess the impact of FeelBetter’s AI-based Precision Population Health Platform on polypharmacy patient management..

波士顿和以色列特拉维夫--（商业新闻短讯）--多药患者管理技术的领先提供商和药物临床情报的先驱FeelBetter今天宣布与波士顿Brigham and Women's Hospital的研究人员合作进行一项前瞻性研究。这项研究将评估FeelBetter基于人工智能的精准人群健康平台对多种药物患者管理的影响。。

Launched in February 2024, the joint study will prospectively follow patients who are receiving care at the hospital’s Phyllis Jen Center for Primary Care, evaluating FeelBetter’s potential as a tool in improving health outcomes and reducing healthcare utilization and costs. This new study follows the publication of retrospective research conducted by investigators at Brigham and Women’s Hospital in 2022, which demonstrated that FeelBetter's Pharmaco-Clinical Intelligence accurately predicts which senior patients are at high risk of medication-related adverse events and recommends relevant and appropriate changes to their medication regimens..

这项联合研究于2024年2月启动，将前瞻性地跟踪在医院Phyllis Jen初级保健中心接受治疗的患者，评估FeelBetter作为改善健康状况、降低医疗利用率和成本的工具的潜力。这项新研究是在Brigham and Women's Hospital研究人员于2022年发表的回顾性研究之后进行的，该研究表明，FeelBetter的药物临床情报准确预测了哪些老年患者处于药物相关不良事件的高风险中，并建议对其药物治疗方案进行相关和适当的改变。。

“Many polypharmacy problems aren’t detected until patients end up in the ER and, in seniors with several chronic diseases and conditions, the simultaneous use of multiple medications ultimately contributes to 10-30% of hospitalizations,” said Lisa Rotenstein, MD MBA MSc, the principal investigator of the study.

该研究的首席研究员、医学博士MBA硕士丽莎·罗滕斯坦（LisaRotenstein）说：“许多多种药物问题直到患者最终进入急诊室才被发现，对于患有多种慢性疾病和病症的老年人来说，同时使用多种药物最终会导致10%至30%的住院率。”。

“Our previous study showed that its platform can be used to identify which patients are at the highest risk of polypharmacy-related adverse events. Based on retrospective data, we’re excited to prospectively examine how the platform can potentially be used to improve patient outcomes, healthcare utilization, and cost efficiencies.”.

“我们之前的研究表明，它的平台可用于确定哪些患者发生多种药物相关不良事件的风险最高。根据回顾性数据，我们很高兴能前瞻性地研究该平台如何潜在地用于改善患者预后，医疗保健利用率和成本效率。”。

David Bates, MD, MSc, Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, added: “Especially for providers like affordable care organizations who are assuming risk for patients, it’s exciting to see new technologies being integrated with EHRs and added to clinical workflows.

哈佛医学院（Harvard Medical School）和布莱根妇女医院（Brigham and Women's Hospital）医学博士、理学硕士大卫·贝茨（David Bates）补充道：“特别是对于像负担得起的医疗机构这样承担患者风险的提供者来说，看到新技术与EHR整合并加入临床工作流程令人兴奋。

Reducing admission rates and downstream costs associated with high-risk patients by implementing evidence-based suggestions around improving their medication regimens will be beneficial for both patients and care teams.”.

通过实施有关改善药物治疗方案的循证建议，降低与高危患者相关的入院率和下游成本，将对患者和护理团队都有益。”。

Presented at the Society of General Internal Medicine (SGIM) 2023 Annual Meeting and the 2023 Annual Research Meeting (ARM) of AcademyHealth, the retrospective research study concluded that FeelBetter can be used to effectively risk stratify emergency department use and hospitalizations among patients with multiple chronic conditions and complex medication regimens.

这项回顾性研究在普通内科学会（SGIM）2023年年会和AcademyHealth 2023年年会（ARM）上发表，结论是FeelBetter可用于有效地对多种慢性病和复杂药物治疗方案患者的急诊科使用和住院进行风险分层。

Study results also indicated that, when paired with a medication management intervention, FeelBetter's technology could potentially reduce healthcare utilization and expenses, and aid in improving patient outcomes..

研究结果还表明，当与药物管理干预相结合时，FeelBetter的技术可能会降低医疗保健的利用率和费用，并有助于改善患者的预后。。

“FeelBetter is on a mission to personalize the way healthcare is delivered, developing purpose-built technology to help clinicians risk stratify polypharmacy patients and proactively prevent related deterioration with timely clinical interventions such as medication regimen changes,” said Yoram Hordan, FeelBetter's CTO, COO, and Co-Founder.

FeelBetter的首席技术官、首席运营官兼联合创始人约拉姆·霍丹（YoramHordan）表示：“FeelBetter的使命是个性化医疗服务的提供方式，开发专门构建的技术，以帮助临床医生对多种药物患者进行风险分层，并通过及时的临床干预（如改变用药方案）主动预防相关恶化。”。

“We’re delighted to expand our research partnership with Brigham & Women’s Hospital with the rollout of the prospective pilot and to be growing the body of evidence in support of our Pharmaco-Clinical Intelligence’s capabilities in improving patient outcomes and driving value-based care.'.

“我们很高兴与Brigham＆Women's Hospital扩大研究合作伙伴关系，推出前瞻性试点，并不断增加证据，以支持我们的药物临床情报在改善患者预后和推动基于价值的护理方面的能力。”。

As part of the pilot, Feelbetter will integrate its platform with Epic’s EHR to enable automated workflows. The FeelBetter platform leverages Pharmaco-Clinical Intelligence, a new category of technology the Company has pioneered combining AI-based analyses and novel, evidence-based pharmacology and clinical capabilities.

作为试点的一部分，Feelbetter将其平台与Epic的EHR集成，以实现自动化的工作流程。FeelBetter平台利用药物临床智能，这是该公司率先将基于AI的分析与新颖的循证药理学和临床能力相结合的一种新技术。

By identifying patients who are at high risk of near-term hospitalization related to polypharmacy issues, providing recommended changes to medication regimens and other needed clinical interventions, and comprehensively monitoring progress, the FeelBetter platform is changing the paradigm in polypharmacy patient management at both the individual and population health levels..

通过识别与多种药物问题相关的短期住院高风险患者，提供药物治疗方案和其他所需临床干预措施的建议变化，以及全面监测进展，FeelBetter平台正在改变个人和人群健康水平上多种药物患者管理的范式。。

About FeelBetter

关于错误

FeelBetter is the pioneer of Pharmaco-Clinical Intelligence, changing the polypharmacy paradigm on both an individual and population health level with a comprehensive solution designed to tackle the challenges associated with suboptimal medication management. Powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate.

FeelBetter是药物临床智能的先驱，通过旨在应对与次优药物管理相关的挑战的综合解决方案，改变了个人和人群健康水平上的多种药物范式。在人工智能和机器学习能力的支持下，FeelBetter的药物临床智能推动个性化药物管理，帮助医疗保健专业人员确保患者的药物治疗方案安全，有效和适当。

The technology pinpoints patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management, and proactively suggests immediate and actionable interventions to reduce these risks. Provider organizations use FeelBetter to monitor their patients' progress and more proactively deliver the right follow-up care, as well as to efficiently allocate resources and minimize preventable, costly use of healthcare services..

该技术针对因药物管理不理想而导致病情恶化和可预防住院的高风险患者，并主动建议立即采取可行的干预措施以降低这些风险。提供者组织使用FeelBetter来监测患者的进展，更积极地提供正确的后续护理，并有效分配资源，最大程度地减少可预防、昂贵的医疗服务使用。。

Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter is headquartered in Boston and Tel Aviv. Investors include Firstime Ventures, Shoni Health Ventures, Triventures, ARC, the innovation hub of Sheba Medical Center, Random Forest VC, The Group Ventures, and GoodCompany Ventures.

由临床医生、临床药剂师和技术专家组成的跨学科团队领导，FeelBetter总部位于波士顿和特拉维夫。投资者包括Firstime Ventures、Shoni Health Ventures、Triventures、ARC、Sheba Medical Center创新中心、Random Forest VC、the Group Ventures和GoodCompany Ventures。

To learn more, visit feelbetter.healthcare..

要了解更多信息，请访问feelbetter。healthcare。。